Cargando…

Eliminating oncogenic RAS: back to the future at the drawing board

RAS drug development has made enormous strides in the past ten years, with the first direct KRAS inhibitor being approved in 2021. However, despite the clinical success of covalent KRAS-G12C inhibitors, we are immediately confronted with resistances as commonly found with targeted drugs. Previously...

Descripción completa

Detalles Bibliográficos
Autores principales: Steffen, Candy Laura, Kaya, Pelin, Schaffner-Reckinger, Elisabeth, Abankwa, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Portland Press Ltd. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9987992/
https://www.ncbi.nlm.nih.gov/pubmed/36688434
http://dx.doi.org/10.1042/BST20221343